Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedMiraMMIRF Cash-to-Debt is 0.00 as of Apr. 2026. The stock has 5 warning signs investors should review. Among 1,393 Biotechnology companies, MedMira ranks worse than 71787.44% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. MedMira's cash to debt ratio for the quarter that ended in Apr. 2026 was 0.00.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, MedMiracouldn't pay off its debt using the cash in hand for the quarter that ended in Apr. 2026.
The historical rank and industry rank for MedMira's Cash-to-Debt or its related term are showing as below:
During the past 13 years, MedMira's highest Cash to Debt Ratio was 0.33. The lowest was 0.00. And the median was 0.02.
MMIRF's Cash-to-Debt is not ranked *
in the Biotechnology industry.
Industry Median: 7.03 * Ranked among companies with meaningful Cash-to-Debt only.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
MedMira Cash-to-Debt Related Terms
MedMira Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for MedMira's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
MMIRF vs VRTX, REGN, MRNA: Cash-to-Debt Comparison
For the Biotechnology subindustry, MedMira's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedMira Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MedMira's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where MedMira's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MedMira (MMIRF) has a Cash-to-Debt of 0.00 as of Apr. 2026. According to the industry distribution chart, MedMira ranks #999999 out of 1393 companies in the Biotechnology industry.
Is MedMira's Cash-to-Debt too high?
MedMira's current Cash-to-Debt is 0.00. Based on the distribution chart, MedMira ranks #999999 out of 1393 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does MedMira's Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, MedMira ranks #999999 out of 1393 companies for Cash-to-Debt. This places MedMira in the lower half of its industry. The industry median Cash-to-Debt is 7.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.03, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedMira's current Cash-to-Debt is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedMira stock overvalued right now?
MedMira (MMIRF) has a current Cash-to-Debt of 0.00. The current Cash-to-Debt is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For MedMira (MMIRF), the current Cash-to-Debt is 0.00 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MedMira Inc is a biotechnology company engaged in the research, development, and manufacturing of rapid diagnostics and technologies. The company operates in one reportable operating segment, rapid diagnostic products and services. Its product line includes HIV, COVID-19, syphilis, Multiplex, Miriad RVF Toolkit, and H. pylori. The company generates revenue from North America, Europe, and other regions, with the majority generated from North America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MMIRF has been successfully added to your 
